PAL coalition member Breast Cancer Action today lambasted the FDA's decision to grant accelerated approval for Avastin® (bevacizumab), in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their

From the Department of Unsurprising News comes a report that PhRMA, the Pharmaceutical Researchers and Manufacturers Association, the brand-name drug industry's lobbying arm, spent $22 Million lobbying Congress in 2007. This is a 25% increase from 2006.

We're excited to announce the launch of a new regular feature on our blog, the PAL Coalition Member Spotlight. Here, we'll be introducing you to our coalition members and giving you the opportunity to hear from them about the work they do and the pressing

Off the labeled path Late last week, the FDA proposed new guidelines on off-label marketing, a follow up to a more nebulous ‘guidance’ it issued in December. The rule change-up would allow drug companies to begin distributing medical journal articles on d

The Royalty Treatment  This survey in JAMA on institutional conflicts of interest at medical schools got some pick up, including these stories Reuters, Inside Higher Ed, Kaiser Daily Health Policy Report.  We blogged on a related editorial by RxP’s Dav

Readers of this blog know that we here at PAL are no fans of Nexium, AstraZeneca's [NYSE:AZN] blockbuster drug for erosive esophagitis, heartburn and Gastroesophageal Reflux Disease (GERD). Nexium, a so-called "proton pump inhibitor," is the successor to

From time to time, we here at Prescription Access Litigation invite members of our coalition of advocacy organizations and labor unions to write guest posts for the PAL blog. We present to you a great post by Marian Sadler, from PAL member National Wome

The Federal Trade Commission announced yesterday that it has filed a lawsuit against Cephalon for paying off four generic drug companies not to bring a generic version of its sleepiness drug, Provigil to market. As the FTC's press release says: The Fed

We interrupt our regular broadcast for a moment of shameless self-promotion. If you like the Prescription Access Litigation blog and the work we do here at PAL to make prescription drugs affordable and hold drug companies accountable for illegal tactics,